About Adlai Nortye
Adlai Nortye is a company based in Hangzhou (China) founded in 2014 by Carsten Lu.. Adlai Nortye has raised $253 million across 3 funding rounds from investors including SDIC, WuXi Biologics and Tigermed. The company has 123 employees as of December 31, 2024. Adlai Nortye operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Hangzhou, China
- Employees 123 as on 31 Dec, 2024
- Founders Carsten Lu
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Adlai Nortye Ltd. Sponsored Adr
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-51.9 M52.45as on Dec 31, 2024
-
EBITDA
$-53.02 M25.48as on Dec 31, 2024
-
Total Equity Funding
$253 M (USD)
in 3 rounds
-
Latest Funding Round
$100 M (USD), Series D
Jul 15, 2021
-
Investors
SDIC
& 13 more
-
Employee Count
123
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Adlai Nortye
Adlai Nortye is a publicly listed company on the NASDAQ with ticker symbol ANL in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Funding Insights of Adlai Nortye
Adlai Nortye has successfully raised a total of $253M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $100 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series D — $100.0M
-
First Round
First Round
(27 Jun 2018)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Series D - Adlai Nortye | Valuation | SDIC , Tigermed | |
| Aug, 2020 | Amount | Series C - Adlai Nortye | Valuation | Tigermed , Yingke Capital | |
| Jun, 2018 | Amount | Series B - Adlai Nortye | Valuation | Matrix Partners China , Yuan Ming Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Adlai Nortye
Adlai Nortye has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include SDIC, WuXi Biologics and Tigermed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Chinese startups are funded and incubated by Legend Star.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Adlai Nortye
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Adlai Nortye
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Adlai Nortye Comparisons
Competitors of Adlai Nortye
Adlai Nortye operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Adlai Nortye
Frequently Asked Questions about Adlai Nortye
When was Adlai Nortye founded?
Adlai Nortye was founded in 2014 and raised its 1st funding round 4 years after it was founded.
Where is Adlai Nortye located?
Adlai Nortye is headquartered in Hangzhou, China. It is registered at Hangzhou, Zhejiang, China.
Is Adlai Nortye a funded company?
Adlai Nortye is a funded company, having raised a total of $253M across 3 funding rounds to date. The company's 1st funding round was a Series B of $53M, raised on Jun 27, 2018.
How many employees does Adlai Nortye have?
As of Dec 31, 2024, the latest employee count at Adlai Nortye is 123.
What does Adlai Nortye do?
Adlai Nortye was established in 2014 in Hangzhou, China, within the biotechnology sector focused on oncology. Therapies utilizing oncolytic viruses to target cancer cells are developed, with operations centered on clinical candidates. REOLYSIN, the lead product, is applied in breast cancer treatment by lysing tumors and stimulating immune responses. Additional programs encompass AN0025 for solid tumors, alongside AN0015 and AN3005 for various tumor types.
Who are the top competitors of Adlai Nortye?
Adlai Nortye's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Is Adlai Nortye publicly traded?
Yes, Adlai Nortye is publicly traded on NASDAQ under the ticker symbol ANL.
Who are Adlai Nortye's investors?
Adlai Nortye has 14 investors. Key investors include SDIC, WuXi Biologics, Tigermed, Tian Ge, and IcbcAmg.
What is Adlai Nortye's ticker symbol?
The ticker symbol of Adlai Nortye is ANL on NASDAQ.